Form 4: VivoSim Labs Director Sells All Common Stock
Insider Transaction Report
VivoSim Labs director David Gobel sold 3,266 shares of common stock at $2.2351 per share, reducing his direct beneficial ownership to zero.
Summary
- David Gobel, a Director of VivoSim Labs, INC. (VIVS), reported the sale of 3,266 shares of common stock.
- The transaction occurred on November 17, 2025, at a price of $2.2351 per share.
- Following this transaction, David Gobel's direct beneficial ownership of VivoSim Labs common stock is 0 shares.
- The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.
- All share numbers reported reflect a 1-for-12 reverse stock split that became effective on March 20, 2025.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a director fully divesting their common stock holdings. However, the execution under a Rule 10b5-1 plan mitigates some of the potential negative implications by indicating a pre-planned sale rather than an immediate reaction to new information.
Positives
- The transaction was made pursuant to a Rule 10b5-1(c) plan, which suggests the sale was pre-scheduled and not based on immediate, non-public information, potentially mitigating concerns about opportunistic insider selling.
Negatives
- A director selling all of their directly held common stock, resulting in zero beneficial ownership, could be perceived negatively by the market, potentially signaling a lack of confidence in the company's future prospects, even if pre-planned.
Risks
- The complete divestment of common stock by a director could lead to negative market sentiment or speculation regarding the company's outlook.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction report is specific to VivoSim Labs and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transaction was made pursuant to a Rule 10b5-1(c) plan, which is a mechanism used by insiders to pre-arrange sales of company stock to avoid accusations of insider trading. | 11/17/2025 | Demonstrates adherence to corporate governance best practices regarding insider trading, providing a defense against claims that the sale was based on material non-public information. |
Stakeholder Impact
- Shareholders may interpret the director's complete divestment as a negative signal, potentially influencing their perception of the company's future value or management's confidence.
Key Dates
| Date | Description |
|---|---|
| 03/20/2025 | Effective date of the 1-for-12 reverse stock split of common stock. |
| 11/17/2025 | Date of the reported transaction where David Gobel sold common stock. |
| 11/19/2025 | Date the Form 4 filing was signed. |
Keywords
VivoSim Labs, VIVS, Form 4, Insider Sale, Director, David Gobel, Common Stock, 10b5-1 Plan, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.